At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase II Study to Assess the Efficacy and Safety of 100IR, 300IR and 500IR Sublingual Tablets of House Dust Mite Allergen for the Treatment of Allergic Rhinitis in an Environmental Exposure Chamber Model
In Brief
A Phase 2 clinical trial evaluating 100 IR house dust mites allergen extract tablet, 300 IR house dust mites allergen extract tablet, and 2 other interventions for Allergic Rhinitis Due to House Dust Mite. Completed, enrolled 355 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the effect of 3 doses of sublingual house dust mite (HDM) tablets versus placebo in the change from baseline of rhinitis total symptom score during the allergen chamber challenge before and after 6 months of treatment.
Study Details
Timeline
Interventions
One sublingual tablet daily during 6 months
One sublingual tablet daily during 6 months
One sublingual tablet daily during 6 months
One sublingual tablet daily during 6 months